阿司匹林抵抗:在埃及的流行和临床结果

IF 0.3 Q4 CRITICAL CARE MEDICINE
Ahmed Salah, Mohammed El-Desuky, Amal Rizk, Amr El-Hadidy
{"title":"阿司匹林抵抗:在埃及的流行和临床结果","authors":"Ahmed Salah,&nbsp;Mohammed El-Desuky,&nbsp;Amal Rizk,&nbsp;Amr El-Hadidy","doi":"10.1016/j.ejccm.2014.12.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response to aspirin may be an explanation for some of these events. Multiple trials have linked aspirin resistance to these adverse events.</p></div><div><h3>Objectives</h3><p>The aim of this study was to estimate the prevalence of aspirin resistance among patients with coronary artery disease (CAD) in Egypt and evaluate its impact on clinical outcome.</p></div><div><h3>Methods</h3><p>A total of 50 patients with documented history of CAD were included; they were on aspirin 150<!--> <!-->mg/day for more than seven days and no other antiplatelet drugs. They were evaluated for aspirin resistance using light transmission aggregometry. Aspirin resistance was defined as a mean aggregation of &gt;20% with 0.5<!--> <!-->mg/ml arachidonic acid. They were followed up after six months for cardiac death, unstable angina (UA), myocardial infarction (MI), and stroke.</p></div><div><h3>Results</h3><p>Prevalence of aspirin resistance was 48% in our study group. Aspirin resistance was significantly higher in patients with family history of CAD (<em>p</em> <!-->=<!--> <!-->0.044), smoking (<em>p</em> <!-->=<!--> <!-->0.011), history of MI (<em>p</em> <!-->=<!--> <!-->0.024), history of percutaneous coronary intervention (PCI) (<em>p</em> <!-->=<!--> <!-->0.001), and concomitant NSAIDs intake (<em>p</em> <!-->=<!--> <!-->0.047). Moreover, aspirin resistance was more common among patients with multi-vessel CAD (<em>p</em> <!-->=<!--> <!-->0.024). Aspirin-resistant patients had a significantly higher rate of UA (<em>p</em> <!-->=<!--> <!-->0.001) and all major adverse cardiac events (MACE) (<em>p</em> <!-->&lt;<!--> <!-->0.001).</p></div>","PeriodicalId":31233,"journal":{"name":"Egyptian Journal of Critical Care Medicine","volume":"3 1","pages":"Pages 23-27"},"PeriodicalIF":0.3000,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejccm.2014.12.001","citationCount":"2","resultStr":"{\"title\":\"Aspirin resistance: Prevalence and clinical outcome in Egypt\",\"authors\":\"Ahmed Salah,&nbsp;Mohammed El-Desuky,&nbsp;Amal Rizk,&nbsp;Amr El-Hadidy\",\"doi\":\"10.1016/j.ejccm.2014.12.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response to aspirin may be an explanation for some of these events. Multiple trials have linked aspirin resistance to these adverse events.</p></div><div><h3>Objectives</h3><p>The aim of this study was to estimate the prevalence of aspirin resistance among patients with coronary artery disease (CAD) in Egypt and evaluate its impact on clinical outcome.</p></div><div><h3>Methods</h3><p>A total of 50 patients with documented history of CAD were included; they were on aspirin 150<!--> <!-->mg/day for more than seven days and no other antiplatelet drugs. They were evaluated for aspirin resistance using light transmission aggregometry. Aspirin resistance was defined as a mean aggregation of &gt;20% with 0.5<!--> <!-->mg/ml arachidonic acid. They were followed up after six months for cardiac death, unstable angina (UA), myocardial infarction (MI), and stroke.</p></div><div><h3>Results</h3><p>Prevalence of aspirin resistance was 48% in our study group. Aspirin resistance was significantly higher in patients with family history of CAD (<em>p</em> <!-->=<!--> <!-->0.044), smoking (<em>p</em> <!-->=<!--> <!-->0.011), history of MI (<em>p</em> <!-->=<!--> <!-->0.024), history of percutaneous coronary intervention (PCI) (<em>p</em> <!-->=<!--> <!-->0.001), and concomitant NSAIDs intake (<em>p</em> <!-->=<!--> <!-->0.047). Moreover, aspirin resistance was more common among patients with multi-vessel CAD (<em>p</em> <!-->=<!--> <!-->0.024). Aspirin-resistant patients had a significantly higher rate of UA (<em>p</em> <!-->=<!--> <!-->0.001) and all major adverse cardiac events (MACE) (<em>p</em> <!-->&lt;<!--> <!-->0.001).</p></div>\",\"PeriodicalId\":31233,\"journal\":{\"name\":\"Egyptian Journal of Critical Care Medicine\",\"volume\":\"3 1\",\"pages\":\"Pages 23-27\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2015-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ejccm.2014.12.001\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Egyptian Journal of Critical Care Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2090730314000309\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Journal of Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2090730314000309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 2

摘要

抗血小板药物阿司匹林被认为是心血管或脑血管疾病患者医学治疗的基石。尽管使用了该药,但仍有相当数量的患者反复出现不良的缺血事件。对阿司匹林反应的血小板聚集的个体间变异性可能是这些事件的一个解释。多项试验已将阿司匹林耐药性与这些不良事件联系起来。目的本研究的目的是估计埃及冠状动脉疾病(CAD)患者中阿司匹林抵抗的患病率,并评估其对临床结果的影响。方法共纳入50例有CAD病史的患者;他们每天服用阿司匹林150毫克,持续7天以上,没有服用其他抗血小板药物。使用光透射聚合法评估他们的阿司匹林耐药性。阿司匹林耐药定义为在0.5 mg/ml花生四烯酸作用下平均聚集率为20%。6个月后随访心源性死亡、不稳定型心绞痛(UA)、心肌梗死(MI)和中风。结果本组患者阿司匹林耐药率为48%。有冠心病家族史(p = 0.044)、吸烟家族史(p = 0.011)、心肌梗死家族史(p = 0.024)、经皮冠状动脉介入治疗(PCI)家族史(p = 0.001)、同时服用非甾体抗炎药家族史(p = 0.047)的患者阿司匹林耐受性明显增高。此外,阿司匹林耐药在多血管冠心病患者中更为常见(p = 0.024)。阿斯匹林耐药患者的UA发生率(p = 0.001)和所有主要心脏不良事件(MACE) (p <0.001)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Aspirin resistance: Prevalence and clinical outcome in Egypt

Introduction

The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response to aspirin may be an explanation for some of these events. Multiple trials have linked aspirin resistance to these adverse events.

Objectives

The aim of this study was to estimate the prevalence of aspirin resistance among patients with coronary artery disease (CAD) in Egypt and evaluate its impact on clinical outcome.

Methods

A total of 50 patients with documented history of CAD were included; they were on aspirin 150 mg/day for more than seven days and no other antiplatelet drugs. They were evaluated for aspirin resistance using light transmission aggregometry. Aspirin resistance was defined as a mean aggregation of >20% with 0.5 mg/ml arachidonic acid. They were followed up after six months for cardiac death, unstable angina (UA), myocardial infarction (MI), and stroke.

Results

Prevalence of aspirin resistance was 48% in our study group. Aspirin resistance was significantly higher in patients with family history of CAD (p = 0.044), smoking (p = 0.011), history of MI (p = 0.024), history of percutaneous coronary intervention (PCI) (p = 0.001), and concomitant NSAIDs intake (p = 0.047). Moreover, aspirin resistance was more common among patients with multi-vessel CAD (p = 0.024). Aspirin-resistant patients had a significantly higher rate of UA (p = 0.001) and all major adverse cardiac events (MACE) (p < 0.001).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
5
审稿时长
42 weeks
期刊介绍: The Egyptian Journal of Critical Care Medicine is the official Journal of the Egyptian College of Critical Care Physicians, the most authoritative organization of Egyptian physicians involved in the multi-professional field of critical care medicine. The journal is intended to provide a peer-reviewed source for multidisciplinary coverage of general acute and intensive care medicine and its various subcategories including cardiac, pulmonary, neuro, renal as well as post-operative care. The journal is proud to have an international multi-professional editorial board in the broad field of critical care that will assist in publishing promising research and breakthrough reports that lead to better patients care in life threatening conditions, and bring the reader a quick access to the latest diagnostic and therapeutic approaches in monitoring and management of critically ill patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信